Febuxostat for treatment of chronic gout

Gray, Charnelda L.; Walters-Smith, Nafesa E.
March 2011
American Journal of Health-System Pharmacy;3/1/2011, Vol. 68 Issue 5, p389
Academic Journal
Purpose. The pharmacology, pharmacokinetics, clinical efficacy, and safety of febuxostat are reviewed. Summary. Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid production through selective inhibition of enzyme xanthine oxidase has been established in short-term Phase II and III clinical trials and long-term open-label studies. Clinical studies have revealed that febuxostat lowers serum uric acid levels more potently than allopurinol while having minimal effects on other enzymes associated with purine and pyrimide metabolism. The most frequent adverse events reported in clinical trials with febuxostat were liver function abnormalities, nausea, arthralgias, and rash. More cardiovascular thromboembolic events occurred in randomized trials in patients treated with febuxostat. Although a causal relationship has not been established, patients should be monitored for signs and symptoms of myocardial infarction and stroke. Febuxostat is available as 40- and 80-mg tablets. The recommended starting dosage is 40 mg orally once daily. If serum uric acid concentrations are not less than 6 mg/dL after two weeks, the dosage can be increased to 80 mg orally once daily. Dosage adjustments are not needed in elderly patients or patients with mild or moderate renal or hepatic impairment. Conclusion. Febuxostat is efficacious as a second-line therapy in lowering serum uric acid levels in patients with gout. Febuxostat may be an alternative for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy.


Related Articles

  • A bout of gout. Lipman, Marvin M. // Consumer Reports on Health;May2011, Vol. 23 Issue 5, p11 

    A personal narrative is presented which explores the author's experience of treating a patient for gout.

  • Difficult-to-Treat Gouty Arthritis: A Disease Warranting Better Management. Schlesinser, Naomi // Drugs;2011, Vol. 71 Issue 11, p1413 

    Gouty arthritis is the most common inflammatory arthritis in adults and is characterized by very painful flares. Gouty arthritis results from an elevated body uric acid pool, which leads to deposition of monosodium urate crystals, mainly in the joints. These crystals trigger the release of...

  • Therapeutic Approaches to Chronic Hyperuricemia and Gout. Grassi, Davide; Pontremoli, Roberto; Bocale, Raffaella; Ferri, Claudio; Desideri, Giovambattista // High Blood Pressure & Cardiovascular Prevention;Dec2014, Vol. 21 Issue 4, p243 

    Gout is currently one of the most common causes of inflammatory arthritis in most industrialised countries. Apart from its high frequency, gout is associated with disability, poor quality of life and increased mortality and therefore represents an ever increasing public health concern....

  • Conference Roundup. AANP 2016 National Conference.  // Clinical Advisor;Jul2016, Vol. 19 Issue 7, p76 

    No abstract available.

  • Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Gaffo, Angelo L.; Saag, Kenneth G. // Core Evidence;2009, Vol. 4 Issue 1, p25 

    Introduction: Gout is a common and disabling cause of arthritis in middle-aged and elderly populations, with its main predisposing factor being hyperuricemia (serum urate > 6.8 mg/dL). Options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and the group...

  • Gout Drugs.  // Arthritis Today;Nov/Dec2009, Vol. 23 Issue 6, p61 

    A chart is presented that list several Anti Gout Drugs including Allopurinol, Febuxostat, and Probenecid.

  • Febuxostat: A Viewpoint by H. Ralph Schumacher Jr and Lan X. Chen. Schumacher, H Ralph; Chen, Lan X // Drugs;2008, Vol. 68 Issue 11, p1875 

    This article focuses on the drug febuxostat and its use for the treatment of gout through its ability to lower uric acid levels in the body. The authors explain the difficulty in diagnosing and treating gout. Febuxostat lowers uric acid in the body and the authors believe it to be safer than the...

  • Krystexxa.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article reports on the approval of the antihyperuricemic drug Krystexxa, an enzyme that lowers uric acid levels which is used to treat gout in adults, manufactured by Savient Pharmaceuticals.

  • Bumpy launch for Savient's new gout drug. Iskowitz, Marc // Medical Marketing & Media;Feb2011, Vol. 46 Issue 2, p10 

    The article focuses on the problems reported by Savient Pharmaceuticals Inc. during the preparations for the launch of its gout drug Krystexxa.

  • Arcalyst Meets Phase III Prophylaxis Endpoint.  // Bioworld Week;6/14/2010, Vol. 18 Issue 24, p4 

    The article reports on the success of IL-1 blocker Arcalyst in preventing gout attacks as shown by the Phase III study conducted by Tarrytown, New York-based Regeneron Pharmaceuticals Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics